Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Mar 9;29(3):1828-1839.
doi: 10.3390/curroncol29030150.

Non-Small-Cell Lung Cancer in 2022: A Review for General Practitioners in Oncology

Affiliations
Review

Non-Small-Cell Lung Cancer in 2022: A Review for General Practitioners in Oncology

Hamid Mithoowani et al. Curr Oncol. .

Abstract

Lung cancer is the leading cause of cancer death in Canada and a significant cause of morbidity for patients and their loved ones. There have been rapid advances in preventing, screening and treating this disease. Here, we present a contemporary review of treatment of non-small cell lung cancer in Canada based on current best practices. The focus of this review is to highlight recent data in screening for lung cancer, management of patients with early and locally-advanced non-small cell lung cancer, as well as management of patients with metastatic disease. There is a special focus on the incorporation of immunotherapy into practice and its associated toxicities.

Keywords: ALK; CAGPO; Canadian Association of General Practitioners in Oncology; EGFR; K-RAS; KRAS; iRAE; iRAEs; immunotherapy; lung cancer; non-small cell lung cancer; screening.

PubMed Disclaimer

Conflict of interest statement

We have read and understood Current Oncology’s policy on disclosing conflicts of interest, and we declare the following interests: H.M. has participated in advisory board meetings for AstraZeneca, Pfizer, Bristol Myers Squibb and Takeda.

Figures

Figure 1
Figure 1
First-line treatment for metastatic non-small-cell lung cancer.

Similar articles

Cited by

References

    1. Jemal A., Center M.M., DeSantis C., Ward E.M. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol. Biomark. Prev. 2010;19:1893–1907. doi: 10.1158/1055-9965.EPI-10-0437. - DOI - PubMed
    1. Ng M., Freeman M.K., Fleming T.D., Robinson M., Dwyer-Lindgren L., Thomson B., Wollum A., Sanman E., Wulf S., Lopez A.D., et al. Smoking prevalence and cigarette consumption in 187 countries, 1980–2012. JAMA. 2014;311:183–192. doi: 10.1001/jama.2013.284692. - DOI - PubMed
    1. Cataldo J.K., Dubey S., Prochaska J.J. Smoking cessation: An integral part of lung cancer treatment. Oncology. 2010;78:289–301. doi: 10.1159/000319937. - DOI - PMC - PubMed
    1. Fares A.F., Jiang M., Yang P., Christiani D.C., Chen C., Brennan P., Zhang J., Schwartz A.G., Landi M.T., Shiraishi K., et al. Smoking cessation (SC) and lung cancer (LC) outcomes: A survival benefit for recent-quitters? A pooled analysis of 34,649 International Lung Cancer Consortium (ILCCO) patients. J. Clin. Oncol. 2020;38:1512. doi: 10.1200/JCO.2020.38.15_suppl.1512. - DOI
    1. Zeng L., Yu X., Yu T., Xiao J., Huang Y. Interventions for smoking cessation in people diagnosed with lung cancer. Cochrane Database Syst. Rev. 2019;6:CD011751. doi: 10.1002/14651858.CD011751.pub3. - DOI - PMC - PubMed

MeSH terms